Navigation Links
BDSI Announces Positive Key Secondary Efficacy Endpoint Results for,Bema Fentanyl

ntanyl through the mucosal membrane and a major need for our target patients."

Dr. Mark Sirgo, President and CEO of BDSI, commented: "These additional efficacy results continue to define the profile of BEMA(TM) Fentanyl in treating breakthrough cancer pain. Based on the combination of what we believe is a convenient and comfortable delivery form with the early pain intensity reduction demonstrated in our study, we remain confident that BEMA(TM) Fentanyl has the potential to play an important role in the future treatment of breakthrough cancer pain. Based on this additional efficacy information, and assuming NDA acceptance and approval by FDA and that our development and commercialization activities will continue as planned, we continue to believe we will ultimately reach our annual peak sales projection of $250 million for the treatment of breakthrough cancer pain."

BDSI recently announced that the New Drug Application (NDA) for BEMA(TM) Fentanyl is scheduled for submission during the third quarter of 2007. Prior to this submission, BDSI will conduct a pre-NDA meeting with the FDA on June 28, 2007 to discuss results of the efficacy trial, along with the safety data and other requirements for the NDA submission.

About the BEMA(TM) Technology

BDSI's BEMA(TM) drug delivery technology consists of a dissolvable, dime-sized polymer disc for application to the mucosal (inner lining of cheek) membrane. BEMA(TM) discs deliver a rapid, reliable dose of drug across mucous membranes for time-critical conditions or trauma cases where intravenous lines or injections are unavailable or not practical.

About BEMA(TM) Fentanyl

BDSI's lead product under development is BEMA(TM) Fentanyl, a treatment for "breakthrough" cancer pain (i.e., episodes of severe pain which "break through" the medication used to control the persistent pain). BDSI believes there is a clear need and growing market for additional narcotic agents in alternative dosage form
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product

Post Your Comments:
(Date:11/23/2009)...,, SANDIEGO,Nov.23/PRNewswire-FirstCall/--NuV...ocusedondevelopingproductsforminimallydisruptivesu...Lukianov,ChairmanandChiefExecutiveOfficer,andMicha...lOfficer,arescheduledtopresentatthe21stAnnualPiper...York,NewYork,onWednesday,December2,2009,at10:00a.m...
(Date:11/23/2009)...,, NORCROSS,Ga.,Nov.23/PRNewswire-FirstCall/-...ingautomatedinstrument-reagentsystemstothebloodtra...entationatthePiperJaffray21stAnnualHealthCareConfe...ouswebcast. ,, TheCompany,spresentationisschedu...e.Accesstothepresentationwillbeavailablethroughthe...
(Date:11/23/2009)...,, POINTRICHMOND,Calif.,Nov.23/PRNewswire-Fir...T )todayannouncedthatitisscheduledtomeetwiththeU.S...iscusstheCompleteResponseLetterregardingtheNewDrug...rtratesublingualtablet).Aspreviouslyannounced,theC...28,2009,indicatedthattheFDAcouldnotapprovetheNDAin...
Breaking Medicine Technology:NuVasive To Present at the Piper Jaffray Health Care Conference and the J.P. Morgan SMid Cap Conference 2NuVasive To Present at the Piper Jaffray Health Care Conference and the J.P. Morgan SMid Cap Conference 3Transcept Pharmaceuticals Scheduled to Meet With FDA to Discuss Intermezzo(R) Complete Response Letter 2Medicare Agency Announces Decreased Payments to Medicare Advantage Insurers in 2010 Says MedicareSupplementPlans com 52350 1Medicare Agency Announces Decreased Payments to Medicare Advantage Insurers in 2010 Says MedicareSupplementPlans com 52350 2Dr John L LeRoy First Atlanta Plastic Surgeon to Perform Newly Approved Dysport Wrinkle Remover Injections for Facial Rejuvenation 52345 1Dr John L LeRoy First Atlanta Plastic Surgeon to Perform Newly Approved Dysport Wrinkle Remover Injections for Facial Rejuvenation 52345 2Dr John L LeRoy First Atlanta Plastic Surgeon to Perform Newly Approved Dysport Wrinkle Remover Injections for Facial Rejuvenation 52345 3Dr David Williams Featured on Searchvitaminsupplements com 52340 1Dr David Williams Featured on Searchvitaminsupplements com 52340 2
...tes second quarter BLA filing for C1-inhibitor,rep...wire-FirstCall/ -- Lev,Pharmaceuticals, Inc. (Lev)... U.S. Phase III trial of C1-esterase inhibitor (C1...dema (HAE). In the,acute study, which is part of t...tary Angioedema Nanofiltration Generation,evaluati...
...arch 15, 2007-- The cause of one notorious,childho... ongoing,threat of another childhood disease, neur...h, researchers from Stony Brook University,report ...oliovirus,is effective in obliterating neuroblasto...viously vaccinated against the virus. , By its nat...
Other Medicine Technology:Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III,Trial for Hereditary Angioedema 2Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III,Trial for Hereditary Angioedema 3Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III,Trial for Hereditary Angioedema 4Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III,Trial for Hereditary Angioedema 5Researchers Use Poliovirus to Destroy Neuroblastoma Tumors in Mice 2Researchers Use Poliovirus to Destroy Neuroblastoma Tumors in Mice 3Researchers Use Poliovirus to Destroy Neuroblastoma Tumors in Mice 4
(Date:11/23/2009)...canCollegeofMedicalGenetics(ACMG)EncouragesFamilie...amilyHistoryDay,Thanksgiving2009 ,, BETHESDA,M...isthesixthannualNationalFamilyHistoryDay,asdeclare...alGenetics(ACMG)encourageseveryonetoknowtheirfamil...potentiallylife-savinginformation,to"starttheconve...
(Date:11/23/2009)...sContinuetoTargetIndividualsintheRecommendedPriori...USNewswire/--TheDepartmentofHealthannouncedtodayth...atlocalStateHealthCentersinDelaware,Lancaster,andL...TheH1N1vaccinewillbeadministeredforfreetoindividua...usaccesstothevaccine.Thedepartmentasksthatonlyindi...
(Date:11/23/2009)...e. Low-income children who don,t access health ca...erm are significantly more likely to have unmet he...to a new study published in the journal Pediatric...g the financing and delivery of quality health car...he current policy debates about health insurance r...
(Date:11/23/2009)...e-quarters getting chemo deal with insomnia, study...ws) -- Insomnia and sleep disorders affect more th...emotherapy, a rate nearly three times higher than ... , The problem is more common in younger patien... University of Rochester Medical Center researcher...
(Date:11/23/2009)...ershipswithMinorityBanksin Washington D.C. , .... IntendedtoSpurEconomicGrowthandRevitalization ...--DaVita,thenation,sleadingproviderofdialysisservi...acostiacommunityfora$1millioninvestmentinIndustria...ycommunities. ,, DaVita,sinvestmentinWashington...
Breaking Medicine News(10 mins):Health News:'Family Health History and Genetics Privacy' is the Newest Addition to the ACMG Genetics & Your Health Video Series 2Health News:Pennsylvania Department of Health Announces Additional H1N1 Vaccination Clinics in Delaware, Lancaster, Lehigh Counties 2Health News:Children who lack continuity with a regular health care provider miss needed services 2Health News:Children who lack continuity with a regular health care provider miss needed services 3Health News:DaVita Launches Minority Bank Initiative with $1 Million Investment in Industrial Bank of Washington, D.C. to Support Underserved Communities 2Health News:DaVita Launches Minority Bank Initiative with $1 Million Investment in Industrial Bank of Washington, D.C. to Support Underserved Communities 3Health News:DaVita Launches Minority Bank Initiative with $1 Million Investment in Industrial Bank of Washington, D.C. to Support Underserved Communities 4
...pay for medical treatment and prescriptions is com...se recovery//, more angina, poorer quality of life...to a study by researchers at Yale School of Medici...utcomes. The 2,498 participants were part of the P...
...ed with aggressive prostate cancer, many men are t...s aggressive treatment// is best. Often this means...o do nothing at all. A new study has found that ei...th those receiving the conservative approach. ...
...he southern Indian state of Tamilnadu has launched... patients. The World Food Programme of the ...h the state government in running this scheme call...day a memorandum of understanding over the project...
...ss of junior doctors in London has received huge f...t, there would be a big rally// which will begin f...lace, and will end at Royal College of Surgeons in...cedure adopted by the government. According to Cam...
... help-line in this megalopolis is becoming hugely ...V/AIDS, having received// over 25,000 texts since ... of the NGO Heroes Project founded by Hollywood ic...uring privacy. It works on the Specific Quer...
...been known to give a boost to the body’s immunity ...g good health//. Now, a Christchurch researcher ha...essing of Vitamin C, demonstrating that apart from...om the Angiogenesis Research Group at the Christch...
Other Medicine News:Health News:Due to Cost, Heart Attack Patients Often Avoid Follow-up Care and Medication 2Health News:Surgery, Radiation Treatment Double Life Expectancy for Prostate Cancer Patients 2Health News:SMS Help-line to Provide Answers for HIV/AIDS Queries 2
Acquidata Uromac Median Urodynamics System
Delphis™ Wireless Urodynamics System
Solenette™ Wireless Urodynamics Systems
...es combined with ease of use make the OM-5 Series ... hospital-based urodynamics, the OM-5 is a complet...pressure, or urethral pressure profiles. Eight (8)...flexible enough to meet the needs of all clinician...
Medicine Products: